Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $62.50

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has been given a consensus recommendation of “Buy” by the nine research firms that are covering the firm, Marketbeat.com reports. Nine investment analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $62.50.

Several equities analysts recently weighed in on JSPR shares. UBS Group started coverage on shares of Jasper Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $38.00 price objective on the stock. BMO Capital Markets started coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price objective on the stock. Royal Bank of Canada cut their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a report on Thursday, January 9th. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Jasper Therapeutics in a report on Tuesday, March 11th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a report on Monday, January 6th.

Institutional Investors Weigh In On Jasper Therapeutics

Several hedge funds have recently bought and sold shares of JSPR. BNP Paribas Financial Markets raised its holdings in shares of Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after acquiring an additional 1,698 shares during the period. MetLife Investment Management LLC raised its holdings in shares of Jasper Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after acquiring an additional 3,873 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Jasper Therapeutics by 106.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock worth $159,000 after acquiring an additional 3,828 shares during the period. EntryPoint Capital LLC acquired a new stake in shares of Jasper Therapeutics during the fourth quarter worth $223,000. Finally, Tema Etfs LLC acquired a new stake in shares of Jasper Therapeutics during the fourth quarter worth $266,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Price Performance

JSPR opened at $5.19 on Monday. Jasper Therapeutics has a one year low of $4.55 and a one year high of $31.01. The company’s 50 day simple moving average is $5.86 and its 200-day simple moving average is $15.49. The stock has a market capitalization of $77.96 million, a P/E ratio of -1.09 and a beta of 2.23.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.35). As a group, analysts anticipate that Jasper Therapeutics will post -4.47 EPS for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.